Emmanuel Hanon, Vicebio CEO (PRNewswire/Viome)
One year after leaving GSK, Emmanuel Hanon jumps to Medicxi-backed vaccine startup with an eye on RSV
After 20 years of service at GSK — leading global vaccines R&D for the last seven — Emmanuel Hanon left last year for a wellness company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
